In this episode, Josh and Michael take a step down from the dizzying heights of HER-2 positive breast cancer treatment and crash back to earth to metastatic pancreatic cancer, a topic that remains an unconquered Everest, mocking oncologists like that one kid who always stole Josh's lunch money in school... Don't worry; there will be no airing of childhood trauma here. Just two oncologists discussing treatments and casting a hopeful eye towards the future.

In this episode, Josh and Michael begin their second two-part expedition, this time exploring HER2-positive breast cancer, an area of oncology that has been much like your favourite Instagram or TikTok celebrity: at the forefront of the hottest new trends. Neither Josh nor Mikey have a favourite Instagram or TikTok celebrity on account of being old and out of touch, but the shifts in HER2-positive breast cancer may be their favourite oncological TikTok celebrity. For the reasons behind such a stretched analogy, listen on!

Metastatic urothelial cancer, when should you use immunotherapy, and how will sequencing change the patient’s potential outcome? Tune in and find out about the current recommendations!

In this extraordinary episode, Josh and Michael continue their journey to the earth's centre and the unknown with more European Society of Medical Oncology (ESMO) highlights. 

Since our last episode, Michael has realised that his French needs a bit of work, so they stuck to their guns and avoided google translate. Josh feels they should work on their Spanish to prepare for ESMO in Madrid in 2023. But before these dashing young Doctors get too excited for next year, more pivotal studies must be reported for your enjoyment! This episode focuses on colorectal, and Michael dabbles in some genitourinary and skin research.

In this very special episode, Josh and Michael hope to fulfil their fantasy of attending the European Society of Medical Oncology's (ESMO) yearly Congress, where they rub elbows with oncology's biggest movers and shakers; learn about the latest groundbreaking studies; and, in Michael's case, speak French with an accent lifted from a Monty Python sketch. The fact that they were stuck at home for the entire conference won't stand in the way of them from highlighting some of the best, most exciting studies presented in Paris.

These vital organs rarely complain; one even regenerates and is a diamond in the rough. But like all organs, they, too, can be damaged by cancer. This episode looks at cutting-edge trials combining treatment modalities! Tune in to find out all there is to know about Topaz and Imbrave

Breast cancer is the most common cancer globally, and deaths occur more in developing nations than in places such as the United States of America or Australia. Resource-rich nations have reduced the mortality of hormone receptor-positive breast cancer through a rigorous screening process and the safe use of endocrine therapy. Tune in to find out more!

Michael and Josh continue to traverse the respiratory system and how lung cancer has evolved due to targeted therapy, molecular markers and a shift away from chemotherapy (which was never that effective!). Tune in as we breathe some fresh air into lung cancer.

The risk of asbestos exposure has decreased drastically over the past 20 years, but mesothelioma is sinister. It may not rear its head for many years, and the consequences can be fatal. Thankfully treatment has progressed with the advent of immunotherapy to slow this affliction. In this episode we explore treatment options unparalleled to what was available five years ago.

Melanoma represents the golden age of cancer treatment, the paradigm shift from chemotherapy to immunotherapy. Gone are the days when melanoma meant a death sentence to those inflicted. Long-term survivors are common, and watching cancer melt away is a reality. Tune into this weeks episode to find out more!

One in six men develops prostate cancer in their lifetime, with the risk exponentially increasing after age 65. It is one of the most common malignancies globally. Thankfully, a large number of treatment options are available! Tune into our inaugural episode that goes through some pivotal practice-changing studies.